key: cord-1018933-fqx60il1
authors: Dillner, J.; Elfström, M.; Blomqvist, J.; Eklund, C.; Lagheden, C.; Nordqvist-Kleppe, S.; Hellström, C.; Olofsson, J.; Andersson, E.; Jernbom Falk, A.; Bergström, S.; Hultin, E.; Pin, E.; Manberg, A.; Nilsson, P.; Hedhammar, M.; Hober, S.; Mattsson, J.; Arroyo Mühr, L. S.; Conneryd Lundgren, K.
title: Antibodies to SARS-CoV-2 and risk of future sickness
date: 2020-09-18
journal: nan
DOI: 10.1101/2020.09.14.20194308
sha: 88d72072447a7c7b8dc4d88a67a5c386b4365c08
doc_id: 1018933
cord_uid: fqx60il1

Background: The extent that antibodies to SARS-CoV-2 may protect against future virus-associated disease is unknown. Method: We analyzed 12928 healthy hospital employees for SARS-CoV-2 antibodies and compared results to participant sick leave records (Clinical trial registration: ClinicalTrials.gov NCT04411576). Results: Subjects with viral serum antibodies were not at excess risk for future sick leave (Odds Ratio (OR): 0.85 (95% Confidence Interval (CI) (0.85 (0.43-1.68)). By contrast, subjects with antibodies had an excess risk for sick leave in the past weeks (OR: 3.34 (2.98-3.74)). Conclusion: Presence of viral antibodies marks past disease and protection against excess risk of future disease.

Background 54 To design strategies for SARS-CoV-2 control, knowledge of whether exposed individuals are 55 immune against future disease is critical [1] . The incubation time from exposure to onset of 56 symptoms has been estimated to last a median of six days, with peak infectiousness occurring 57 zero to two days before onset of symptoms [2] and pre-symptomatic spread is estimated to 58 account for a substantial proportion of disease transmission [2, 3] . Infectiousness decreases with 59 increasing time after onset of symptoms [4] and some individuals may remain asymptomatic 60 despite being virus positive [5] . The IgG response develops rather slowly, commonly 61 concomitantly with symptom resolution and increases in subsequent weeks. One report found that 62 all COVID-19 patients had become seropositive 19 days after onset of symptoms [6] . Although 63 there are many studies on viral antibodies and immunity, it is still uncertain to what extent 64 immunity exists and what the predictive value of presence of viral antibodies is. A problem is that 65 studies that are based on past sickness are fraught with recall biases (subjects knowing their 66 antibody status preferentially recalling events) and that prospective studies using future sickness 67 as endpoint need to be very large. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.14.20194308 doi: medRxiv preprint

The Karolinska University Hospital is one of the largest university hospitals in Europe, with 80 about 15,300 employees (employment during enrollment, 23rd April -22nd May 2020). The 81 hospital announced that all employees who were at work (without ongoing sickness) were 82 welcome to participate in a study on SARS-CoV-2. We enrolled 14,057 participants who all 83 signed a written informed consent that also included permission to extract data from the 84 employer's administrative databases that contain data on sick leave. Most participants were 85 between 30-59 years old and 79% were females (Supplementary Table 1 ). Analysis results were 86 reported to participants, but analyses took 4 weeks post sampling to complete. Sick leave data 87 was obtained from 6 weeks before sampling until 2 weeks after sampling. The study was 88 approved by the National Ethical Review Agency of Sweden (Decision number 2020-01620). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.14.20194308 doi: medRxiv preprint

We invited all employees currently at work at a large hospital in Sweden to participate in a 155 longitudinal cohort study of SARS-CoV-2 testing in relation to both past and future sick leave. 156 We enrolled 14,052 participants ( Figure 1 ). After exclusion of participants not formally 157 employed (e.g. medical students) and subjects with invalid tests, the final cohort consisted of 158 12,928 subjects with complete data on sick leave and valid SARS-CoV-2 antibody results ( Figure   159 1).

The overall number and proportion of employees that tested positive in the antibody tests are 161 shown by age in ten-year spans in Table 1 . The proportion of serology-positive subjects was 162 greatest among the youngest employees and decreased significantly with increasing age (p-value 163 for trend <0.0001).

Positivity in serology was significantly associated with an excess risk for having been on sick 165 leave in the past 6 weeks (Table 2) but did not confer any excess risk for future sick leave for the 166 coming two weeks after testing ( Table 2 ). The mutual adjustments (age, sex and serostatus) in the 167 multivariate model had only minor effects on the estimates (Supplementary Table 2 ).

As Covid-19 is known to preferentially affect older subjects and have a long sickness duration, 169 we next analyzed the length of sick leave in relation to age and serology status (Table 3) . No past 170 sick leave was found for 66% of the antibody-negative subjects, whereas only 35% of the 171 antibody-positive subjects had no past sick leave (Table 3 ). The association of seropositivity with 172 past sick leave was highly significant (OR: 3.34 (2.98-3.74)) and mostly due to sick leave longer 173 than five days (Table 3 ). Figure 2 displays the proportion of participants on sick leave in relation 174 to their antibody status. The typical seasonal pattern with reported sick leave declining over time 175 during spring was seen for both seronegative and seropositive subjects (Figure 2 ), but the 176 elevated excess odds ratio for past sick leave was similar for the different weeks before testing. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.14.20194308 doi: medRxiv preprint each other after testing (Figure 2 ), in line with the absence of excess risk after testing (Table 2) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 18, 2020 . . https://doi.org/10.1101 /2020 We conclude that antibody testing is a powerful tool for identification of subjects who have had 228 prior virus exposure and are protected against future disease. Although it is commonly assumed 229 that antibodies mark immunity, it is important that it has now been shown in a large cohort study 230 that seropositive subjects have no excess risk for future sick leave. 231 We would like to caution that there is a large number of serology tests currently on the market 232 and the extent of their validation may vary. Also, none of these tests have been specifically 233 validated for the indication proposed here (to separate exposed subjects who are protected from 234 future disease from exposed subjects at risk to develop disease in the future).

In summary, the present study has found that validated antibody testing may be helpful in SARS-

CoV-2 screening strategies as antibody-positive subjects were found to have no excess risk for 237 future disease in the weeks after testing. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.14.20194308 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 18, 2020 . . https://doi.org/10.1101 /2020 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 18, 2020 . . https://doi.org/10.1101 /2020 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.14.20194308 doi: medRxiv preprint Table 3 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.14.20194308 doi: medRxiv preprint

Defining the Epidemiology of Covid-19 -Studies

Total n, % (95% CI)